Research study for adults with glioblastoma


An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma


Purow Benjamin, W

Adults 18 years and older with newly diagnosed glioblastoma (GBM) following surgery are invited to participate in a research study. The purpose of the study is to compare how well the investigational cancer vaccine, Rindopepimut (CDX-110), improves overall survival versus standard-of-care treatment. Standard-of-care treatment for GBM typically combines surgery, radiation therapy, and chemotherapy. Rindopepimut (CDX-110) is an investigational agent in this study – it is not yet FDA-approved for glioblastoma or any other indication. During the study, this vaccination is given after radiation treatment is complete, once per month for 6-12 months. To qualify, you must be newly diagnosed GBM and the tumor must have a genetic mutation called EGFRvIII (present in about 35% of GBM). • Study-related experimental medication provided free of charge. • Participant’s insurance company will be billed for standard of care exams and procedures. • No compensation is provided for this study. For more information please contact: • Kim Chapman • Phone: (434)243-9360 • Email: • IRB-HSR # 16533 Principal Investigator: Benjamin Purow, MD Department of Neuro-Surgery, Neuro-Oncology Division


Brain Cancer
Brain Tumor

Cancer (Oncology)


No Compensation

Kim Chapman